Lung Cancer | Specialty

Promising Emerging Classes of Therapies in NSCLC

February 13th 2013

Molecular Heterogeneity in Non-Small Cell Lung Cancer

February 13th 2013

Selecting Treatment for First- Line Non-Squamous NSCLC

February 13th 2013

Selecting a Laboratory for Molecular Testing in NSCLC

February 13th 2013

Rebiopsying and Molecular Testing in NSCLC

February 13th 2013

Molecular Testing and Actionable Targets in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part II

February 13th 2013

Concurrent Versus Sequential Testing in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part I

February 13th 2013

Introduction: Advances and Issues in NSCLC

February 13th 2013

Squamous Cell Carcinoma Treatment Options

February 13th 2013

Biotech Focus: Tracking the Oncology Pipeline

February 13th 2013

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

Targeting Tumors Early: Trials Push Novel Agents to Forefront

February 11th 2013

New discoveries about tumor biology suggest to many researchers that targeted therapies, when used in appropriate early-stage patients, might significantly boost cure rates and extend lives.

BATTLE-2: Next-Generation of Biomarker-Driven Trials

February 8th 2013

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Innovative BATTLE Trials Pair Agents, Biomarkers in NSCLC

February 7th 2013

As therapy based on cell-signaling pathways has become a priority in cancer research, so has the concept of designing clinical trials that can better target patient populations more likely to benefit from a particular regimen.

Dr. Ramalingam Explores Cytotoxics in Lung Cancer

January 22nd 2013

Suresh S. Ramalingam, MD, from Emory University's Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

Dr. DeRosa Discusses Nab-Paclitacel in Lung Cancer

January 21st 2013

William T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.

Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial

January 17th 2013

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

Priority Review Granted to Afatinib for EGFR+ Advanced NSCLC

January 15th 2013

The FDA has accepted a NDA for afatinib to treat patients with locally advanced or metastatic NSCLC who have tested positive for an EGFR mutation that has been identified through a companion diagnostic test.

Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC

January 15th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.